CEBP CTRC-AACR San Antonio Breast Cancer Symposium Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rudd, M. F.
Right arrow Articles by Houlston, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rudd, M. F.
Right arrow Articles by Houlston, R. S.
Cancer Epidemiology Biomarkers & Prevention Vol. 13, 2268-2270, December 2004
© 2004 American Association for Cancer Research


Short Communication

MTHFR Polymorphisms and Risk of Chronic Lymphocytic Leukemia

Matthew F. Rudd1, Gabrielle S. Sellick1, Ruth Allinson1, Estella Matutes2, Daniel Catovsky2 and Richard S. Houlston1

1 Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom and 2 Section of Haemato-Oncology, Institute of Cancer Research, London, United Kingdom

Requests for reprints: Richard Houlston, Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey SM2 5NG United Kingdom. Phone: 44-208-722-4175; Fax: 44-208-722-4362. E-mail: richard.houlston{at}icr.ac.uk

Folate availability is critical for DNA integrity, required for the transfer of methyl groups in the biosynthesis of thymidilate. Reduction of 5,10-methylenetetrahydrofolate, a donor for methylating dUMP to dTMP in DNA synthesis, to 5-methyltetrahydrofolate, the primary methyl donor for methionine synthesis, is catalyzed by 5,10-methylenetetrahydrofolate reductase (MTHFR). The MTHFR polymorphisms C677T and A1298C have been shown in some studies to alter the risk of a range of different malignancies. We evaluated the role of the C677T and A1298C polymorphisms on chronic lymphocytic leukemia (CLL) risk by genotyping 832 patients and 886 healthy controls. The odds ratio of CLL associated with 677CT and 677TT genotypes were 1.02 [95% confidence interval (95% CI), 0.83-1.24] and 0.90 (95% CI, 0.66-1.24), respectively. The odds ratio of CLL associated with 1298AC and 1298CC genotypes were 0.97 (95% CI, 0.79-1.18) and 0.88 (95% CI, 0.62-1.24), respectively. This data indicate that the MTHFR polymorphisms C677T and A1298C do not significantly contribute to an inherited genetic susceptibility to CLL.

Key Words: chronic lymphocytic leukemia • MTHFR • polymorphism




This article has been cited by other articles:


Home page
haematolHome page
D. Gemmati, A. Ongaro, S. Tognazzo, L. Catozzi, F. Federici, E. Mauro, M. Della Porta, D. Campioni, A. Bardi, G. Gilli, et al.
Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival
Haematologica, April 1, 2007; 92(4): 478 - 485.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.